01 / Research notes
Metabolism is not a treatment claim
Research interest in MOTS-c often turns into claims about weight loss, exercise performance, or bone health. Preclinical findings and studies of an analogue cannot establish those results for a compounded MOTS-c product. Weight change or bone loss deserves a conventional assessment with measurable goals.
02 / Research notes
Policy scope
HHS discusses MOTS-c acetate for specified injectable forms under its source, testing, labeling, reporting, and patient-specific prescription conditions. That is a limited enforcement position, not a blanket permission to sell a vial or publish a dosing protocol.
03 / Research notes
Discuss risks first
Human safety information for MOTS-c remains limited. Peptide quality and contamination are meaningful concerns. Review medicines, medical history, and evidence-based metabolic or bone care with a clinician.
Evidence and safety in context
MOTS-c is being researched for metabolic effects. Preclinical work or results from an analogue do not show that a compounded MOTS-c product treats obesity or osteoporosis in people.
FDA reports that it has not identified human exposure data for MOTS-c drug products administered by any route. That leaves basic questions about side effects, repeated exposure, and product quality unanswered.
Questions for a clinical visit
- Is the goal weight management, bone health, fatigue, or another issue?
- What measurements and approved treatments are appropriate for that goal?
- What information exists for the exact proposed product rather than an analogue?
See how the HHS policy works and how to prepare for a consultation.
Common questions about MOTS-c
Does MOTS-c cause weight loss?
Clinical benefit for weight loss has not been established for a MOTS-c product.
Is there a standard MOTS-c dosage protocol?
There is no FDA-approved MOTS-c dosing regimen. A website chart cannot replace individualized clinical evaluation.
Is MOTS-c FDA approved?
No. The HHS interim policy does not approve a MOTS-c drug product.
Important information
HHS's interim policy is conditional and may be revisited. Compounded products are not FDA approved and have not undergone FDA review for safety, effectiveness, or quality before marketing. Treatment through Jonathan Larson MDPC requires a clinical evaluation; a licensed provider decides whether any prescription is medically necessary and appropriate. This guide is informational and is not medical advice.
Read the HHS policy ↗